ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Evaluation of a Risk-Stratified Induction Immunosuppression Protocol Utilizing Low-Dose Antithymocyte Globulin in Renal Transplantation.

A. Diamond, Z. Khawaja, M. Simpson, S.-C. Kung, M. Akoad, J. Pomposelli, E. Pomfret.

Solid Organ Transplantation & Hepatobiliary Diseases, Lahey Hospital and Medical Center, Burlington, MA.

Meeting: 2016 American Transplant Congress

Abstract number: 225

Keywords: Dosage, Graft survival, Infection, Rejection

Session Information

Date: Monday, June 13, 2016

Session Name: Concurrent Session: Kidney: Induction Therapy 1

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:30pm-3:42pm

Location: Room 312

Related Abstracts
  • Evaluation of Dose Dependent Rabbit Anti-Thymocyte Globulin Induction in Risk-Stratified Kidney Transplant Recipients.
  • Pancreas Transplantation Immunosuppression Induction With Rabbit Antithymocyte Globulin +/- Rituximab and Early Steroid Withdrawal: Experience With >500 Recipients

Lower doses of rabbit-derived antithymocyte globulin (rATG) may result in less infection and cost, but may increase the incidence of acute rejection. We compared the safety and efficacy of a risk-stratified rATG dosing protocol.

53 patients received renal transplants between January 2014 and September 2015. Low risk patients received 0.75 mg/kg x 3 doses and high risk patients received 1.25 mg/kg x 3 doses. 41 patients met inclusion criteria (23 low dose, 18 high dose). The primary outcome was biopsy-proven acute rejection (BPAR) at twelve months. Secondary outcomes include twelve month patient and graft survival, infectious complications, and delayed graft function. A cost analysis was also performed.

BPAR as well as patient and graft survival were similar between groups at twelve months. Donor and recipient characteristics, infectious complications, and graft function were also comparable. Average costs were reduced by approximately 40% in the low dose group. Additional information is in Table 1.

 

Low-Dose

High-Dose

p-value

Recipient age at transplant, (years), mean

56

51

NS

Donor age (years), mean

46

45

NS

Expanded criteria donor (%)  9 11  NS
Donor after cardiac death (%) 9  17   NS 
Living donor (%)  30 38   NS 

Biopsy-proven acute rejection (%)

26

20

NS

Graft loss (%)

8

5

NS

Patient death (%)

4

5

NS

Delayed graft function (%) 30 17 NS

CMV viremia (%)

13

17

NS

Urinary tract infection (%) 39 33 NS

Cost per patient (USD), mean

5,182

9,216

<0.001

Our findings indicate that low risk patients achieve acceptable outcomes with low dose rATG. Initial analysis suggests that the use of low dose rATG provides a similar efficacy and safety profile. A cost savings of approximately $100,000 was achieved with this risk-stratified protocol in just 23 patients. Follow-up continues in order to determine the impacts on long-term outcomes.

CITATION INFORMATION: Diamond A, Khawaja Z, Simpson M, Kung S.-C, Akoad M, Pomposelli J, Pomfret E. Evaluation of a Risk-Stratified Induction Immunosuppression Protocol Utilizing Low-Dose Antithymocyte Globulin in Renal Transplantation. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Diamond A, Khawaja Z, Simpson M, Kung S-C, Akoad M, Pomposelli J, Pomfret E. Evaluation of a Risk-Stratified Induction Immunosuppression Protocol Utilizing Low-Dose Antithymocyte Globulin in Renal Transplantation. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/evaluation-of-a-risk-stratified-induction-immunosuppression-protocol-utilizing-low-dose-antithymocyte-globulin-in-renal-transplantation/. Accessed March 1, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Left-Sided Donor Nephrectomy Predisposes Living Kidney Donors to Latent Adrenal Insufficiency with Symptoms of Fatigue and Inferior Quality of Life.
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.